Overview

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Status:
Terminated

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

To assess progression-free survival at the combination dose determined in the Phase 1 portion of the study, and safety of sunitinib combined with exemestane in patients with metastatic or locally-recurrent, unresectable breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Exemestane
Sunitinib